Fig. 1: Observed neutralizing antibody titer against ancestral SARS-CoV-2 (D614G) and Omicron BA.1 variant after 50 µg of mRNA-1273.214 and mRNA-1273 administered as second booster.
From: Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Unadjusted, observed pseudovirus neutralizing geometric mean titers (GMT [95% CI]) are provided for all participants regardless of prior SARS-CoV-2 infection pre-booster and those with and without SARS-CoV-2 infection, against the Omicron BA.1 variant (a) and ancestral SARS-CoV-2 (D614G) (b). Data are from participants with non-missing data at the time point. Eight participants in the mRNA-1273 50-µg group were missing pre-booster SARS-CoV-2 status. Antibody values reported as below the lower limit of quantification ([LLOQ] 18.5 for ancestral SARS-CoV-2 [D614G]; 19.9 for omicron BA. 1) were replaced by 0.5 × LLOQ. Values greater than the upper limit of quantification ([ULOQ] 45,118 for ancestral SARS-CoV-2 [D614G]; 15502.7 for Omicron BA.1) were replaced by the ULOQ if actual values are not available. 95% CIs were calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation. Observed nAb GMTs are summarized in Table S6.
